Selective cytokine inhibitory drugs for treating disorders of the central nervous system

Details for Australian Patent Application No. 2004220607 (hide)

Owner Celgene Corporation

Inventors Schafer, Peter H.

Agent Phillips Ormonde Fitzpatrick

Pub. Number AU-B-2004220607

PCT Pub. Number WO2004/080393

Priority 60/452,374 06.03.03 US

Filing date 5 March 2004

Wipo publication date 23 September 2004

Acceptance publication date 11 June 2009

International Classifications

A61K 31/553 (2006.01) - having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine

A61K 31/554 (2006.01) - having at least one nitrogen and at least one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem

A61K 45/06 (2006.01) Medicinal preparations containing active ingredients not provided for in groups

Event Publications

29 September 2005 PCT application entered the National Phase

  PCT publication WO2004/080393 Priority application(s): WO2004/080393

11 June 2009 Application Accepted

  Published as AU-B-2004220607

8 October 2009 Standard Patent Sealed

29 September 2011 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This patent ceased under section 143(a), or Expired. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004220609-Cryotherapy method for detecting and treating vulnerable plaque

2004220605-Reducing discomfort caused by electrical stimulation